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enrollment/disenrollment dates, timing of the index event,
and the database time span. Projecting expenditure on an
annual or per member per month basis requires standard-
izing these periods of observation. We evaluate bias in-
troduced by a simple method for annualizing utilization
and cost measures. METHODS: We investigated resource
use and costs surrounding an index event; hospital ad-
mission with a primary diagnosis of heart failure. For
each patient, claims data were available for a pre-event
and post-event period ranging from 6 to 24 months. We
standardized periods to one year pre- and post-event by
first tabulating counts and costs for the actual period ob-
served. We then multiplied these values by the ratio of
365 days to actual days in the period such that values for
periods shorter than 365 days were inflated and longer
than 365 days deflated. To determine whether this ad-
justment biased the magnitude of annualized values, we
estimated a regression model with annualized cost and
adjustment ratio as dependent and independent variables
respectively. RESULTS: For the pre-event period, there
was no significant association between annualized cost
and adjustment factor (p  0.72, R2  0.00014, p 
0.012) indicating absence of bias. While bias was ob-
served in the post-event adjustment factor (p  0.005),
the low model explanatory power (R2  0.00869) and
lack of correlation (Pearson correlation coefficient 0.093)
suggest minimal impact on the magnitude of annualized
estimates. CONCLUSION: We find that a simple approach
to standardization was reasonably robust. We compare
advantages and disadvantages with more complex regres-
sion-based methods.
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BACKGROUND: Fabry disease (FD) is a rare genetic
disorder of metabolism due to a deficiency of a lysosomal
enzyme (alpha-galactosidase A) and the resultant accu-
mulation of globotriasylceramide in the cerebrovascular
and cardiovascular systems, kidney, and liver. Symptoms
become manifest during childhood or adolescence and
progress to include episodes of extremity pains, renal fail-
ure, cardiomyopathy, and/or strokes. OBJECTIVES: To
better understand quality of life (QOL) in FD patients
relative to disease progression, and normatively, com-
pared to other chronic diseases. METHODS: Data were
collected prospectively from a sample of 85 FD patients
contacted through the Fabry Support and Information
Group. Subjects responded to a survey that included the
SF-36, a symptoms checklist, and extensive demographic
questions. Information about SF-36 performance for
other populations was collected from the literature. Data
on 53 males are reported here. RESULTS: Patients with
FD have substantially lower QOL across all domains
compared to the 25th percentile of the general male pop-
ulation, as well as that observed for patients with Gau-
cher disease, renal disease, and stroke. There is also a very
substantial decrease in QOL from early adulthood through
middle age (data not shown here). CONCLUSIONS: These
data suggest that FD places an increasing and unusually
heavy QOL burden on patients, especially related to gen-
eral health, physical role and vitality. Research is cur-
rently underway to determine whether enzyme replace-
ment therapy can alleviate this burden. (See table below.)
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Negative affectivity (NA) has been shown to be strongly
and consistently correlated to patient reported, subjective
health indicators. Therefore, subjective health indicators
may or may not give an accurate assessment of the indi-
vidual’s true health status. NA can be expected to act as a
general nuisance factor in health research, one that taps
organically spurious variance. The pervasive influence of
NA may confound the results and complicate the inter-
pretation of health related quality of life instruments,
such as the SF-36. OBJECTIVE: The purpose of this
study was to evaluate the potential influence of NA on
the MOS SF-36. METHODS: We used Structural Equa-
Table for PQP9
SF-36 Scores FD Males
General US Male Population
(25th Percentile)
Gaucher Disease
(Untreated) Stroke
Renal Disease
(Hemodialysis)
Physical Function 52 80 67 65 82
Role Physical 28 75 52 54 68
Bodily Pain 49 62 65 75 70
General Health 28 62 51 64 51
Vitality 35 50 42 55 59
Social Functioning 56 75 71 86 75
Role Emotional 53 67 64 80 75
Mental Health 63 68 65 80 69
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tion Modeling (SEM) techniques to evaluate the SF-36
and the impact of NA on the Mental and Physical Com-
ponents in a sample taken from the 1990 National Sur-
vey of Functional Health Status (NHS). RESULTS: The
percent of shared variance of the Physical Health and
Mental Health indicators and the Physical and Mental
Health factors combined are physical function (.0603),
role physical (.0817), bodily pain (.0720), health percep-
tion (.0600), role emotional (.0486), vitality (.0756), gen-
eral mental health (.5207) and social function (.0811).
General mental health (GMH) indicators are virtually
identical to NA indicators. The percent of shared vari-
ance of the NA/GMH factor and Physical Health and
Mental Health is .4422 and .9781 respectively. CON-
CLUSIONS: The present results suggest that about 47
percent of Physical Health and 98 percent of Mental
Health is due to the influence of NA/GMH. This may ac-
count for the lack of discriminative ability, shown in pre-
vious studies, of the Mental Health factor and Mental
Component Scale Score.
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OBJECTIVE: Recently, interest has increased in produc-
tivity loss associated with medical conditions or health
behaviors that do not preclude attendance at work (e.g.,
migraine, smoking). Commonly, productivity loss is sub-
jectively assessed (asking workers directly to report on
the productivity impacts of their medical conditions or
health behaviors) which may be problematic because cer-
tain illnesses or health behaviors are viewed as socially
undesirable. We describe the initial validation of a new
instrument, the Health and Work Questionnaire (HWQ)
that can be used in studies of worker health and produc-
tivity. METHOD: The HWQ consists of 24 items assess-
ing work quality, quantity, efficiency, and related factors.
To minimize “social desirability” tendencies on the part
of respondents, they are asked to rate their work quality,
quantity, and efficiency from their supervisor’s and their
co-worker’s perspectives as well as their own. All items
have ten-point response scales. The initial questionnaire
was pretested by 30 subjects. Based on subject feedback,
no wording changes were deemed necessary. The HWQ
was administered to 294 employees of a major US airline
and was completed at baseline and at three subsequent
monthly intervals. Validation included comparisons with
two objective productivity measures collected by the air-
line: Time Lost, the average time a reservation agent is
unavailable between calls; and Total Performance Points,
the performance measure used for quarterly employee
evaluation. RESULTS: Six subscales were identified by
factor analyses: productivity, concentration/focus, supervi-
sor relations, impatience/irritability, work satisfaction, and
non-work satisfaction. Internal consistency reliability val-
ues were high for all scales (0.84–0.96), with the exception
of impatience/irritability, displaying adequate reliability
(0.72). All HWQ scale scores correlated significantly with
the Time Lost measure; two scales correlated significantly
with the performance measure. The significant correlations
were all modest (0.12 to 0.22). CONCLUSIONS: With
other measures, the HWQ may be a useful instrument in
assessing group differences and evaluating the impact of
health interventions on work-place productivity.
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Pharmaceutical science has moved away from focusing
exclusively on the impact of medications on physiological
parameters to a focus that includes the subject’s quality
of life (QoL). To date, QoL assessment has relied exclu-
sively on global summaries that ask subjects to recall,
summarize, and evaluate their subjective QoL. New sci-
ence-based methods using handheld technology to gather
QoL data can lead to more valid, reliable, and timely
QoL data. Many of the components of QoL, from subjec-
tive well-being to objective functioning, derive from an
interest in understanding a subject’s daily and momen-
tary experiences. Rather than relying on broad summa-
ries of experience, a ‘bottoms-up’ approach to QoL as-
sessment directly measures subjects’ momentary QoL in
real-time, in the real-world. Until recently, researchers
did not have an efficient way to collect valid momentary
QoL data from subjects in their natural environment. Re-
cent methodological advances in the science of patient
experience, termed Ecological Momentary Assessment
(EMA), make it possible to collect real-time QoL data
from subjects using electronic patient experience diaries.
This ‘bottoms-up’ approach using EMA methods extends
existing QoL measures by providing a unique perspective
on the extent to which subjects’ evaluations of various
moments in their lives reflect QoL changes over time. Re-
cent empirical evidence suggests that this ‘bottoms-up’
approach may enhance the sensitivity of QoL assessment
in clinical trials. The new perspective EMA provides on
momentary patient experience represents a promising
methodological advancement in the study of QoL. In
combination with standard written assessments of QoL,
EMA data can provide a new perspective on the relation-
ship between medication effects and QoL.
